Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) EBITDA: 2019-2024

Historic EBITDA for Agilon Health (AGL) over the last 6 years, with FY2024 value amounting to -$279.9 million.

  • Agilon Health's EBITDA rose 224.99% to -$127.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$362.7 million, marking a year-over-year decrease of 758.82%. This contributed to the annual value of -$279.9 million for FY2024, which is 2489.46% down from last year.
  • According to the latest figures from FY2024, Agilon Health's EBITDA is -$279.9 million, which was down 2489.46% from -$224.1 million recorded in FY2023.
  • Agilon Health's EBITDA's 5-year high stood at -$54.5 million during FY2020, with a 5-year trough of -$369.9 million in FY2021.
  • Its 5-year average for EBITDA is -$206.0 million, with a median of -$224.1 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 57912.91% in 2021, then soared by 7256.92% in 2022.
  • Annual analysis of 5 years shows Agilon Health's EBITDA stood at -$54.5 million in 2020, then plummeted by 579.13% to -$369.9 million in 2021, then soared by 72.57% to -$101.5 million in 2022, then tumbled by 120.87% to -$224.1 million in 2023, then decreased by 24.89% to -$279.9 million in 2024.
  • Its EBITDA stands at -$279.9 million for FY2024, versus -$224.1 million for FY2023 and -$101.5 million for FY2022.